Remove Article Remove Clinical Trials Remove Data Remove Programs
article thumbnail

A Bipartisan Bill Is Pledging $75 Million for Psychedelic Research in Military PTSD Treatment

Veriheal

This article will delve into this historic legislation’s potential benefits and implications. The Grant Program Details The heart of this landmark legislation lies in the development of a robust grant program. With this step, the U.S.

article thumbnail

Article: Intellectual Property Due Diligence in Psychedelics

Cannabis Law Report

Unlike novel chemical compounds that are synthetically produced in the pharmaceutical industry through drug development programs, psychedelic compounds have a long and established history. As we see more data emerge from clinical trials, we are likely to see patent applications covering stability, pharmacokinetic, and pharmacodynamic data.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Vice Article: Australians Can Get a Medicinal Cannabis Prescription for Pretty Much Anything

Cannabis Law Report

First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

article thumbnail

Cannabis 3.0 Accelerates Access to Consumer and Medical Research

Cannabis Law Report

Virtual Clinical Trials transcend geographic, mobility and economic barriers. Clinical trials are medical research projects involving human participants. However, the costs of conducting a full-scale clinical trial can be prohibitive, posing barriers to research for cannabis companies.

article thumbnail

More than half of prescriptions for medicinal cannabis in Australia given in Queensland, study says

Cannabis Law Report

Medicinal cannabis products such as capsules, creams, oils, lozenges, sprays and granulated flowers were approved for prescription 159,665 times between the start of Australia’s medicinal cannabis program in February 2016 and September 2021, research led by the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics shows.

article thumbnail

MedXtractor Fills a Key Gap in Mental Health Treatments

Cannabis Law Report

s (CSE: MXT) (OTC: MXTTF) SHAMAN and YMI programs apply machine learning to high-resolution health records to better diagnose mental health disorders. In addition, the company aims to predict what treatments are most effective in addressing these conditions, including psychedelics, which have shown tremendous promise in early clinical trials.

article thumbnail

Study on MDMA for Traumatic Brain Injury Boosted By $1.5M Donation

SpeedWeed

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. Wesana outlined five key goals: Gain expertise and information to design psychedelic-assisted therapy programs for TBI and improve the Wesana timeline and path to market for its treatments.